Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Molecular and Structural Effects of Percutaneous Interventions in Chronic Achilles Tendinopathy

Darrieutort-Laffite C., Soslowsky LJ., Le Goff B.

Clinical Trial on Tendon Injury, published in Int J Mol Sci (2020) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Mol Sci (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32977533
PMCID
PMC7582801
DOI
10.3390/ijms21197000
Citations
14

Abstract (original English)

Achilles tendinopathy (AT) is a common problem, especially in people of working age, as well as in the elderly. Although the pathogenesis of tendinopathy is better known, therapeutic management of AT remains challenging. Various percutaneous treatments have been applied to tendon lesions: e.g., injectable treatments, platelet-rich plasma (PRP), corticosteroids, stem cells, MMP inhibitors, and anti-angiogenic agents), as well as percutaneous procedures without any injection (percutaneous soft tissue release and dry needling). In this review, we will describe and comment on data about the molecular and structural effects of these treatments obtained in vitro and in vivo and report their efficacy in clinical trials. Local treatments have some impact on neovascularization, inflammation or tissue remodeling in animal models, but evidence from clinical trials remains too weak to establish an accurate management plan, and further studies will be necessary to evaluate their value.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Achilles TendonAnimalsHumansDisease Models, AnimalChronic DiseaseAdrenal Cortex HormonesAngiogenesis InhibitorsStem Cell TransplantationTendinopathyPlatelet-Rich Plasma

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research